ipl-logo

Aurobindo Pharma Case Study

941 Words4 Pages

Aurobindo pharma Ltd. has evolved itself into a knowledge driven, R&D focused company, with its manufacturing and marketing infrastructure spread across many countries, to become a conglomerate in the world of pharmaceutical generics. Also as written in the vice-chairman’s message in the annual report the company is focusing on 4 major strategic imperatives of business performance (Productivity, Market Share, Portfolio and Profitability). along with this 4 major strategic initiatives the company is also inclined to increase its product portfolio strategically to maintain its position in the market and move towards its goal of becoming the leading generic pharmaceutical manufacturer.
Since 2012 Aurobindo pharma has emphasised on its quality …show more content…

Their major focus has been on countries such as Japan, Australia, Brazil, Latin America, Russia and the Middle East. Aurobindo Pharma has consolidated its R&D base with establishment of its second Center for Chemical Research dedicated to active pharmaceutical ingredient (API) research with additional resources aimed at fortifying its product range and clinical research initiatives. Aurobindo pharma is looking to capitalize on its generic products in the developed markets through its strong manufacturing base, authorized by US FDA, MHRA (UK), WHO, MCC (South Africa), Anvisa (Brazil) for both active pharmaceutical ingredients (APIs) and formulations. This would help it improve its profit margins, also fuelled by developing market for its high value top 10 products, large volume sales of its existing product by ramping up operation and production, and introduce products with high entry barriers, which are a part of its mid-term to long-term …show more content…

The number of in-licensing deals is increasing over recent years and all MNCs are actively seeking acquisitions and licensing agreements as a more cost effective means of gaining access to generics, and novel products than carrying out intensive in-house R&D. Aurobindo pharma is also looking to strategically co-work and increase collaborative alliances to improve its growth trajectory and become the leading generic drug manufacturer in the world.
While having the intent to grow and become the largest pharmaceutical company in the world, Aurobindo pharma looks to do business in such a manner which is beneficial to the society & environment, thus increasing its social responsibility. They look to take inputs from all their stake holders as they believe in social integration. Their CSR policy resolves around 5 basic

Show More
Related

  • Marketing Plan For Allround: OTC Cold Medicine

    670 Words  | 3 Pages

    PharmaSIM- Marketing Plan MKTG 613: MARKETING MANAGEMENT Professor Suresh Ramanathan TEAM GAMMA SEVEN Britton Eastburn Temitope Kayode-Ojo Brian Newbury Harsha Srinivasan Introduction: The ALLSTAR brand is one of the leading manufacturers of packaged goods in the world. The company was started in 1924 and it now consists of a consumer product, an international and a pharmaceutical division. The pharmaceutical division of the company produces and markets ethical and OTC medicine.

    Read More

  • The Pros And Cons Of The Pharmaceutical Industry

    1631 Words  | 7 Pages

    Nowadays it seems like legal drugs are more expensive than illegal ones. This dilemma occurs because the pharmaceutical industry affects the economy significantly. Although the United States is a mixed market economy, there are instances where the economy seems like a free market economy. A free market economy allows companies to determine the prices of goods free from government intervention. The pharmaceutical industry, despite several regulations set by the food and drug administration, is a free market economy.

    Read More

  • Austin As A Lobbyist Essay

    1177 Words  | 5 Pages

    A look at how one man and his backing help keep an entire pharmaceutical company in the position of running a monopoly. This man is named

    Read More

  • Arguments Against Big Pharma

    1087 Words  | 5 Pages

    Every citizen in the United States has individual rights protected by the Constitution. This protection also includes businesses that have gone through the legal process to become a legal entity ; more commonly known as becoming a corporation. Many times these individual rights, protected by the Constitution, conflict with the common good and as history shows, the courts consistently side with the common good when faced with a case that pits these two against each other. Big Pharma are corporations exercising their individual rights to market, and sell their product to consumers. In the process, the common good is suffering.

    Read More

  • Johnson & Johnson Value Chain Analysis Summary

    942 Words  | 4 Pages

    Johnson & Johnson currently has a 10.4% market share of the Pharmaceutical Manufacturing industry. They have the second largest share of this industry, just behind Amgen at 10.9%. By looking at the revenue and operating income for Johnson & Johnson, we can see their margins and evaluate their performance. Johnson & Johnson’s operating profit margin improved from 2015 to 2016 but decreased significantly from 2016 to 2017. The operating profit margin for the company as a whole in 2016 was 28.72% and in 2017 it was 24.07% (Appendix A).

    Read More

  • Johnson & Johnson Case Analysis

    1623 Words  | 7 Pages

    Background and Introduction: Johnson & Johnson is an American multinational organization that was founded in 1886. This company consists of pharmaceutical and consumer packaged goods. Johnson & Johnson has been headquartered in New Jersey. This organization has operations on over 57 countries and their products are sold on over 175 countries. Their calendar has a worldwide sale of $65 billion for 2011.

    Read More

  • Human Body During The Renaissance

    1668 Words  | 7 Pages

    For that reason, is why the we have modern pharmaceutical industry, and the world of patent

    Read More

  • Assess The Strengths And Weaknesses Of Merck

    825 Words  | 4 Pages

    The goal is to make a lifechanging medication at an affordable price. Also, owning a lot of patents under their name has helped them earn a lot of profits. The Merck company has succeeded in differentiating itself as cost leadership

    Read More

  • Pharmacology Case Study

    443 Words  | 2 Pages

    Pharmacology Assignment Week 4 Marty Smith is a 67-year-old male who has called 911 after experiencing chest pain and dizziness. The paramedics arrive and notice a bottle of nitroglycerin on the table. The patient states he has angina and is to take the medication as needed for chest pain. He took one pill an hour ago and a second pill 10 minutes prior to calling 911.

    Read More

  • Nestle Corporate Social Responsibility Case Study

    3469 Words  | 14 Pages

    1) Evaluate how Nestlé 's approach to corporate responsibility was good for their business. Corporate businesses generally have to meet ethical, legal, commercial and public expectations. That is what is expected of the business world today. This is known as the Corporate Social Responsibility (CSR). However, businesses with short-term goal will rarely practice CSR since practicing it does not bring any benefit.

    Read More

  • Johnson International Corporation: Case Analysis: Johnson International Corporation

    800 Words  | 4 Pages

    Johnson International Corporation (JIS) is a global company that offers logistical support to the military and private companies which employs 100 people and it is largely located in US, Europe and Far East. It has been doing business for last 15 years and it had a net income after tax of $10 million. 70 % of their business is related to military sector and its focus is to provide logical support to military and private sector. In this company the president and chief executive officer were the same person and he/she was responsible for the overall activities of the company. The company has cut the budget in various field including the budget in IT capital and human resource which includes training for employee.

    Read More

  • Porter's Five Forces In The Pharmacy Industry

    1156 Words  | 5 Pages

    The number of acquisitions is not so high and it depends more upon the organic expansion. • These pharmacies face informative and predictable risk from the variability of “generic conversion” • Inability of the company to keep stride with the growing private labeled brands popularity. • The in-store implementation of the store formats and services is not consistent at every

    Read More

  • Porter's Five Forces Analysis Pharmaceutical Industry

    720 Words  | 3 Pages

    Many new companies to enter the market without burden of costly tasks such as research and development, clinical trials and manufacturing of drugs. Moreover, patent expiry is one of the reasons which is offering opportunities for lower cost generic manufacturer in terms of greater market access. Additionally, the government has increased their focus on healthcare cost cutting. It is creating pressure on the authority to allow early introduction of low-cost drugs in the

    Read More

  • Case Study: Janssen Pharmaceutica '

    1472 Words  | 6 Pages

    There is large investments being made in new technology to reduce production times and improve quality so that patients receive the best quality products in the swiftest manner. Patient care is at the heart of Janssen as clinical trials are on site to always try to gain more information on the potential products to improve. Janssen is a subsidiary of Johnson & Johnson, so to look at the organisation structure it must fall under J&J’s structure first. J&J’s organisation can be split into three main factions; Consumer healthcare, medical devices and pharmaceuticals.

    Read More

  • Rorer Converts-Poulenc Case Study

    2104 Words  | 9 Pages

    INTRODUCTION The latter decade of the 20th century brought a number of major innovations to the pharmaceutical industry, most notably a remarkable wave of successful joint ventures and mergers between big and medium players in the market. In this case study we analyzed the Rorer and Rhône-Poulenc (RP) merger in July 31, 1990 that created a major multinational company: the Rhône-Poulenc Rorer, Inc. (RPR), where the RP became the majority shareholder, owning 68 percent of the RPR’s shares. Prior to the merger, Rorer lacked the resources to access the European market, and the firm presented relatively low cash balance and rising debt which, according to financial analysts, appeared to be handicapping its strategy of growth by acquisitions.

    Read More

More about Aurobindo Pharma Case Study

Open Document